Evidence map›Paper›PMID 40765018›Full record

ArticleAddiction science & clinical practice2025

Design of a randomized tobacco cessation trial among FDNY World Trade Center responders in a lung cancer screening program.

David G Goldfarb, Tyrone Moline, David J Prezant, Matthew P Bars, Rachel Zeig-Owens, Theresa Schwartz, Madeline F Cannon, Brandon Vaeth, Julia H Arnsten, Mayris P Webber and 1 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in Addiction science & clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05997225 (Preventing Lung Cancer Through Tobacco Cessation at FDNY), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05997225 phase4completednot on this map

Preventing Lung Cancer Through Tobacco Cessation at FDNY

TypeinterventionalSponsorAlbert Einstein College of MedicineRan2024 to 2025Enrolled23ConditionsTobacco Use, Tobacco Smoking, Tobacco Use CessationArmsopt out enrollment, tailored counseling, varenicline started prior to target quit date, opt in enrollment, non-tailored counseling, varenicline started prior to target quit date
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

David G GoldfarbMontefiore Medical Center, Bronx, NY, USA. David.goldfarb@fdny.nyc.gov.
Tyrone MolineMontefiore Medical Center, Bronx, NY, USA.
David J PrezantMontefiore Medical Center, Bronx, NY, USA.
Matthew P BarsFire Department of the City of New York (FDNY), 1 Pierrepont Plaza, 11th floor, Brooklyn, NY, 11201 11E-07K, USA.
Rachel Zeig-OwensMontefiore Medical Center, Bronx, NY, USA.
Theresa SchwartzMontefiore Medical Center, Bronx, NY, USA.
Madeline F CannonMontefiore Medical Center, Bronx, NY, USA.
Brandon VaethMontefiore Medical Center, Bronx, NY, USA.
Julia H ArnstenMontefiore Medical Center, Bronx, NY, USA.
Mayris P Webber *Montefiore Medical Center, Bronx, NY, USA.
Shadi Nahvi *Montefiore Medical Center, Bronx, NY, USA.

Funding

Mentoring investigators to improve health outcomes among persons with opioid and tobacco use disorderK24DA051807 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Shadi Nahvi · 2022 to 2026
$972k
NIDA NIH HHS K24 DA051807NIH HHS K24DA051807NIOSH CDC HHS 5R21OH012256NIOSH CDC HHS 75D301-22-R-72142
6 · The paper itself

Abstract

backgroundCigarette smoking remains the leading preventable cause of death, posing heightened risks for vulnerable populations. World Trade Center (WTC) disaster responders face an elevated burden of respiratory diseases, and despite access to an evidence-based tobacco cessation program, a subset continues to smoke cigarettes. Treatment engagement remains a critical barrier, as many people who smoke fail to enroll in or adhere to programs, particularly when participation requires decisions to actively opt-in to treatment. This randomized controlled trial integrates tobacco treatment into an existing low-dose computed tomography (LDCT) lung cancer screening program and compares the effectiveness of an Enhanced Care intervention with opt-out enrollment and biofeedback to Standard Care with opt-in enrollment and standard treatment.

methodsThe trial includes retired Fire Department of the City of New York (FDNY) responders aged 50 years or older who have a smoking history that satisfies either the National Comprehensive Cancer Network criteria of at least 20 pack-years or a simplified criterion of at least 20 years of smoking. Participants are randomized to either Enhanced Care, featuring opt-out enrollment in tobacco treatment with tailored counseling using biofeedback from chest LDCT and spirometry results, or Standard Care, requiring opt-in enrollment and standard tobacco treatment without biofeedback. Both arms receive a varenicline regimen with 4 weeks of pre-loading. Primary outcomes are treatment enrollment and biochemically verified 7-day abstinence. Factors associated with enrollment and abstinence, including retention, adherence, and quit motivation, will be evaluated. DISCUSSION: This trial addresses a key gap in tobacco cessation research by testing an innovative intervention for a high-risk occupational cohort participating in LDCT screening. The Enhanced Care model integrates opt-out enrollment, personalized biofeedback, and varenicline preloading to reduce smoking rates and health burdens in FDNY responders. Findings aim to inform scalable cessation strategies for both occupational and general populations, highlighting the need for novel approaches for hard-to-treat individuals who smoke.

trial registrationThis trial was registered at ClinicalTrials.gov under the identifier NCT05997225.

Indexed as

Early Detection of CancerEmergency RespondersFirefightersLung NeoplasmsSeptember 11 Terrorist AttacksSmoking CessationTobacco Use CessationAgedFemaleHumansMaleMiddle AgedNew York CityRandomized Controlled Trials as TopicTomography, X-Ray ComputedBiofeedback interventionLDCT screeningOpt-out enrollmentSmoking cessation interventionWorld trade center

Identifiers

PMID40765018
PMCPMC12323262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.